Form 4: Director John Milligan Receives PACB Stock Option Grant

Pacific Biosciences director John F. Milligan was granted 223,492 stock options as part of his compensation package.

Summary

• Director John F. Milligan received a grant of 223,492 stock options on June 3, 2026.
• The options have an exercise price of $1.58 per share.
• The options are set to expire on June 3, 2036.
• Vesting occurs monthly over a one-year period, contingent on continued service as a director.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that carries no significant market-moving sentiment.

Positives

• Aligns director incentives with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the options, potentially affecting director retention or incentive alignment.

Future Outlook

The options vest monthly over one year, provided the director remains in service, indicating a standard retention-based equity structure.

Industry Context

StockSavvy.ai notes that equity grants for non-employee directors are standard practice in the biotechnology sector to ensure board members are incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The use of monthly vesting over one year for director equity is consistent with standard corporate governance practices for mid-cap biotech firms.
• The grant size is typical for board-level compensation in the life sciences industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution upon future exercise of options.

Next Steps

• Director to continue service to satisfy vesting requirements.

Key Dates

Keywords

PACB, Pacific Biosciences, Director Compensation, Stock Options, Insider Transaction, Form 4